Legend Biotech (LEGN) Non-Current Deffered Revenue (2019 - 2025)
Legend Biotech (LEGN) posted Non-Current Deffered Revenue of -$277000.0 for Q2 2025, down 106.72% on a QoQ basis from -$134000.0 in Q1 2025, and up 5.46% year-over-year from -$262657.0 in Q2 2024.
Legend Biotech (LEGN) has 7 years of Non-Current Deffered Revenue data on file, last reported at -$277000.0 in Q2 2025.
- In Q2 2025, Non-Current Deffered Revenue rose 5.46% year-over-year to -$277000.0; the TTM figure through Jun 2025 stood at -$277000.0 (up 5.46% YoY), while the FY2023 annual figure was $48.0 million, up 15722.8% from the prior year.
- Non-Current Deffered Revenue retreated to -$277000.0 in Q2 2025, from -$134000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $48.0 million in Q4 2023 and bottomed at -$484000.0 in Q3 2023.
- A 5-year average of $2.8 million and a median of -$188000.0 in 2021 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue sank 158.77% — and 2024, when it gained 18.61%.
- Year by year, Non-Current Deffered Revenue stood at -$295000.0 in 2021, then climbed by 20.68% to -$234000.0 in 2022, then soared by 20596.58% to $48.0 million in 2023, then sank by 100.9% to -$430000.0 in 2024, then soared by 35.58% to -$277000.0 in 2025.
- The last three Non-Current Deffered Revenue figures came in at -$277000.0 (Q2 2025), -$134000.0 (Q1 2025), and -$430000.0 (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -277,000.00 |
| Mar 31, 2025 | -134,000.00 |
| Sep 30, 2024 | -430,000.00 |
| Jun 30, 2024 | -293,000.00 |
| Mar 31, 2024 | -157,000.00 |
| Dec 31, 2023 | 47.96 Mn |
| Sep 30, 2023 | -484,000.00 |
| Jun 30, 2023 | -360,000.00 |
| Mar 31, 2023 | -131,000.00 |
| Sep 30, 2022 | -234,000.00 |
| Jun 30, 2022 | -156,000.00 |
| Mar 31, 2022 | -77,000.00 |
| Dec 31, 2021 | -295,000.00 |
| Sep 30, 2021 | -219,000.00 |
| Jun 30, 2021 | -144,000.00 |
| Mar 31, 2021 | -71,000.00 |
| Dec 31, 2020 | -114,000.00 |
| Dec 31, 2019 | 277.77 Mn |